Due to the change in drug tariff pricing since October 2025 of bimatoprost and bimatoprost/timolol single dose unit (SDU) preservative-free (PF) eye drops, the switch from these products to the multidose products Bimi®, Eyreida® and Eyzeetan® has been suspended.

There are ongoing supply issues with Eyreida® and Eyzeetan®.

Practices will not be disadvantaged by this change when performance is assessed and measured at the end of the financial year.

The ScriptSwitch switch messages have been removed and the EMIS searches related to this switch have also been updated.

A new search has been uploaded to the NCL Enterprise - Search & Reports section in EMIS Reporting to replace this.

Ensure the new search named Sustainable Eye Drops for Glaucoma v1.5 is uploaded and the previous version is removed.

Communication regarding this change has been sent to all practices directly.

This item was updated on Tuesday 20 January to reflect the change to the search name in EMIS Reporting.